## Supplementary Table 6. Use of phosphodiesterase-5 inhibitors

|               | Low-risk group (n=97) | High-risk group (n=117) |
|---------------|-----------------------|-------------------------|
|               | Yes       | No     | Yes   | No     |
| Age (y)       |           |        |       |        |
| 60–64         | 1 (1.0)   | 2 (2.1)| 0 (0.0)| 0 (0.0)|
| 65–70         | 9 (9.3)   | 16 (16.5)| 23 (19.7)| 13 (11.1)|
| 71–80         | 15 (15.5)| 42 (43.3)| 6 (5.1)| 44 (37.6)|
| 81–90         | 1 (1.0)  | 9 (9.3) | 2 (1.7)| 19 (16.2)|
| ≥91           | 0 (0.0)   | 2 (2.1)| 0 (0.0)| 2 (1.7)|
| Sex           |           |        |       |        |
| Male          | 23 (23.7)| 71 (73.2)| 32 (27.4)| 78 (66.7)|

Values are presented as number (%).